TrialHepatology international2021

Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase II study (ALTER-0802 study).

Yongkun Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.